Keyword: Carmot Therapeutics
Carmot Therapeutics' series B will carry its lead Type 2 diabetes drug through clinical proof of concept.
Carmot will use its lead-identification technology to provide Amgen with a stream of prospects against conditions including Parkinson’s disease.
Carmot Therapeutics has secured its second major partnership. The latest is a discovery and licensing deal with Roche’s Genentech.